Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REGV131 LNP1265

Drug Profile

REGV131 LNP1265

Alternative Names: REGV 131 LNP 1265

Latest Information Update: 03 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intellia Therapeutics
  • Developer Intellia Therapeutics; Regeneron Pharmaceuticals
  • Class Antihaemorrhagics; Blood coagulation factors; Gene therapies
  • Mechanism of Action Factor IX replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia B

Most Recent Events

  • 23 Apr 2024 Regeneron Pharmaceuticals plans the phase-I/II BEYOND-9 trial for Haemophilia B (In children, In adolescents, In adults) in July 2024 (IV) (NCT06379789)
  • 22 Feb 2024 US FDA approves IND application for gene editing therapeutics in Haemophilia B
  • 22 Feb 2024 Intellia Therapeutics and Regeneron plans a first-in-human phase I trial for Haemophilia B in mid-2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top